cefazolin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 530 25953-19-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefazolin
  • cefazolin sodium
  • cefamezin
  • cefaprim
  • cefazoline
  • cephamezine
  • cephazolin
  • cephazoline
  • cefazolin sodium salt
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
  • Molecular weight: 454.50
  • Formula: C14H14N8O4S3
  • CLOGP: -1.09
  • LIPINSKI: 1
  • HAC: 12
  • HDO: 2
  • TPSA: 156.09
  • ALOGS: -2.97
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 33 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 80 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 146.75 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.89 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.18 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 4, 1973 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 452.90 13.11 184 14441 21709 53312732
Anaphylactic reaction 220.61 13.11 158 14467 58168 53276273
Arthrodesis 157.94 13.11 48 14577 2388 53332053
Hypotension 146.76 13.11 255 14370 253821 53080620
Postoperative wound infection 119.85 13.11 56 14569 9210 53325231
Acute generalised exanthematous pustulosis 102.49 13.11 52 14573 10229 53324212
Fatigue 85.95 13.11 47 14578 730459 52603982
Bronchospasm 72.07 13.11 49 14576 16549 53317892
Exposure during pregnancy 71.42 13.11 125 14500 124735 53209706
Urticaria 67.53 13.11 128 14497 135757 53198684
Erythema 64.99 13.11 137 14488 156832 53177609
Vitamin K deficiency 61.49 13.11 16 14609 448 53333993
Amniotic cavity infection 61.38 13.11 20 14605 1250 53333191
Shoulder arthroplasty 60.66 13.11 26 14599 3489 53330952
Drug hypersensitivity 59.97 13.11 184 14441 265058 53069383
Limb operation 57.08 13.11 25 14600 3534 53330907
Blood pressure decreased 55.07 13.11 76 14549 61793 53272648
Type I hypersensitivity 53.72 13.11 22 14603 2635 53331806
Cardiac arrest 49.96 13.11 91 14534 93576 53240865
Drug-induced liver injury 47.79 13.11 49 14576 29184 53305257
Tachycardia 46.56 13.11 96 14529 108116 53226325
Anaesthetic complication 45.81 13.11 18 14607 1936 53332505
Rash 43.88 13.11 239 14386 445952 52888489
Recurrence of neuromuscular blockade 42.91 13.11 9 14616 94 53334347
Premature baby 41.41 13.11 38 14587 19763 53314678
Renal failure 40.67 13.11 96 14529 118356 53216085
Kounis syndrome 37.60 13.11 14 14611 1301 53333140
Hypoprothrombinaemia 37.42 13.11 10 14615 311 53334130
Vascular purpura 36.35 13.11 14 14611 1427 53333014
Toxic epidermal necrolysis 35.85 13.11 38 14587 23512 53310929
Renal injury 35.48 13.11 26 14599 9878 53324563
Hepatic function abnormal 35.36 13.11 47 14578 36852 53297589
Purpura senile 35.01 13.11 11 14614 611 53333830
Tarsal tunnel syndrome 34.62 13.11 11 14614 634 53333807
Disseminated intravascular coagulation 33.96 13.11 34 14591 19685 53314756
Anhedonia 33.71 13.11 26 14599 10661 53323780
Fear 32.99 13.11 31 14594 16610 53317831
Drug intolerance 32.80 13.11 8 14617 205485 53128956
Alopecia 32.26 13.11 12 14613 234571 53099870
Product dose omission issue 31.49 13.11 7 14618 191613 53142828
Acute hepatic failure 30.97 13.11 30 14595 16690 53317751
Headache 30.96 13.11 63 14562 536758 52797683
Pseudomembranous colitis 30.92 13.11 16 14609 3275 53331166
Injury 30.36 13.11 52 14573 50919 53283522
Death 30.29 13.11 32 14593 357200 52977241
Thrombotic microangiopathy 30.07 13.11 23 14602 9314 53325127
Post procedural complication 29.18 13.11 29 14596 16637 53317804
Unevaluable event 28.83 13.11 50 14575 49448 53284993
Hyperthermia malignant 28.36 13.11 10 14615 795 53333646
Red man syndrome 28.12 13.11 11 14614 1169 53333272
Multiple organ dysfunction syndrome 27.05 13.11 52 14573 55625 53278816
Coagulopathy 26.87 13.11 30 14595 19668 53314773
Post procedural haematoma 26.24 13.11 11 14614 1397 53333044
Shock 26.15 13.11 32 14593 23107 53311334
Sinusitis 26.05 13.11 7 14618 168557 53165884
Weight increased 25.64 13.11 12 14613 204555 53129886
Maternal exposure during delivery 25.63 13.11 10 14615 1055 53333386
Resorption bone increased 24.96 13.11 10 14615 1132 53333309
Device related infection 24.93 13.11 31 14594 22755 53311686
Peripheral swelling 24.47 13.11 13 14612 206095 53128346
Pain in extremity 23.63 13.11 26 14599 285024 53049417
Tonic clonic movements 23.54 13.11 10 14615 1312 53333129
Toxic skin eruption 23.26 13.11 23 14602 13116 53321325
Vestibular disorder 22.91 13.11 10 14615 1401 53333040
Face oedema 22.89 13.11 28 14597 20212 53314229
Spinal cord haematoma 22.76 13.11 6 14619 177 53334264
Implant site haematoma 21.81 13.11 5 14620 81 53334360
Asthenia 21.81 13.11 38 14587 343552 52990889
Malaise 21.41 13.11 41 14584 357576 52976865
Generalised tonic-clonic seizure 20.73 13.11 32 14593 28726 53305715
Premature delivery 20.17 13.11 30 14595 26074 53308367
Post procedural haemorrhage 20.07 13.11 17 14608 7951 53326490
Shock haemorrhagic 19.93 13.11 18 14607 9165 53325276
Oxygen saturation decreased 19.91 13.11 56 14569 76669 53257772
Altered state of consciousness 19.85 13.11 29 14596 24807 53309634
Systemic lupus erythematosus 19.77 13.11 5 14620 125409 53209032
Hepatitis cholestatic 19.66 13.11 16 14609 7083 53327358
Staphylococcal bacteraemia 19.34 13.11 14 14611 5219 53329222
Hypoventilation 19.26 13.11 13 14612 4336 53330105
Circulatory collapse 18.85 13.11 27 14598 22687 53311754
Joint swelling 18.78 13.11 22 14603 234616 53099825
Heparin-induced thrombocytopenia 18.73 13.11 13 14612 4536 53329905
Clostridium difficile infection 18.67 13.11 30 14595 27863 53306578
Pleural effusion 18.60 13.11 60 14565 88519 53245922
Laryngeal dyspnoea 18.40 13.11 5 14620 166 53334275
Pyomyositis 18.36 13.11 6 14619 378 53334063
Sphingomonas paucimobilis infection 18.31 13.11 3 14622 6 53334435
Deep vein thrombosis 18.18 13.11 57 14568 82856 53251585
Hypoxia 17.88 13.11 44 14581 55636 53278805
Manipulation 17.86 13.11 4 14621 58 53334383
Alanine aminotransferase increased 17.83 13.11 62 14563 95033 53239408
Pain 17.81 13.11 92 14533 588306 52746135
Eosinophilic pneumonia acute 17.70 13.11 6 14619 424 53334017
Drug reaction with eosinophilia and systemic symptoms 17.63 13.11 32 14593 32768 53301673
Oligohydramnios 17.48 13.11 14 14611 6062 53328379
Swelling 17.46 13.11 16 14609 191089 53143352
Abdominal wound dehiscence 17.29 13.11 5 14620 209 53334232
Dizziness 17.20 13.11 49 14576 372210 52962231
Procedural complication 17.14 13.11 13 14612 5199 53329242
Toxicity to various agents 17.14 13.11 21 14604 219577 53114864
Injection site pain 16.97 13.11 5 14620 113386 53221055
Pulseless electrical activity 16.95 13.11 15 14610 7439 53327002
Aspartate aminotransferase increased 16.82 13.11 56 14569 83973 53250468
Insomnia 16.69 13.11 16 14609 187056 53147385
Nasopharyngitis 16.52 13.11 17 14608 192278 53142163
Hypokalaemia 16.45 13.11 61 14564 96456 53237985
Therapeutic product effect decreased 16.32 13.11 7 14618 125648 53208793
Linear IgA disease 16.31 13.11 8 14617 1462 53332979
Laryngeal oedema 16.22 13.11 13 14612 5632 53328809
Haemolytic anaemia 16.16 13.11 17 14608 10422 53324019
Arthralgia 16.14 13.11 64 14561 439719 52894722
Wound 15.74 13.11 3 14622 91554 53242887
Bradycardia 15.71 13.11 49 14576 71007 53263434
Clostridium difficile colitis 15.68 13.11 23 14602 19742 53314699
Jaundice acholuric 15.51 13.11 4 14621 108 53334333
Emotional distress 15.47 13.11 30 14595 32287 53302154
Irregular breathing 15.46 13.11 5 14620 305 53334136
Cholestasis 15.43 13.11 28 14597 28667 53305774
Foetal growth abnormality 15.37 13.11 3 14622 21 53334420
Thrombophlebitis superficial 15.34 13.11 12 14613 5023 53329418
Muscle spasms 15.27 13.11 9 14616 134786 53199655
Renal vein thrombosis 15.24 13.11 5 14620 319 53334122
Mycobacterial peritonitis 15.20 13.11 4 14621 117 53334324
Haemodynamic instability 15.13 13.11 15 14610 8579 53325862
Weight decreased 14.87 13.11 26 14599 234922 53099519
Blood immunoglobulin A decreased 14.84 13.11 5 14620 347 53334094
Decorticate posture 14.73 13.11 5 14620 355 53334086
Arthrofibrosis 14.71 13.11 3 14622 27 53334414
Influenza 14.65 13.11 4 14621 95375 53239066
Cerebral infarction 14.63 13.11 25 14600 24419 53310022
Keratitis fungal 14.63 13.11 4 14621 136 53334305
Serratia test positive 14.61 13.11 3 14622 28 53334413
Fall 14.56 13.11 50 14575 358390 52976051
Acute kidney injury 14.51 13.11 119 14506 253749 53080692
Renal impairment 14.49 13.11 53 14572 83265 53251176
Chest expansion decreased 14.42 13.11 3 14622 30 53334411
Angioedema 14.31 13.11 34 14591 42042 53292399
Bradycardia foetal 14.25 13.11 5 14620 392 53334049
Foetal exposure during pregnancy 13.98 13.11 30 14595 34685 53299756
Treatment failure 13.95 13.11 9 14616 128394 53206047
Vertigo positional 13.88 13.11 9 14616 2807 53331634
Normal newborn 13.52 13.11 13 14612 7166 53327275
Nausea 13.30 13.11 138 14487 755953 52578488
Stevens-Johnson syndrome 13.23 13.11 24 14601 24558 53309883
Multiple lentigines syndrome 13.22 13.11 4 14621 196 53334245

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 306.92 14.98 139 12607 14895 32485885
Anaphylactic reaction 218.44 14.98 140 12606 30032 32470748
Hypoprothrombinaemia 147.52 14.98 34 12712 385 32500395
Fear 90.52 14.98 56 12690 11263 32489517
Kounis syndrome 84.30 14.98 31 12715 1937 32498843
Renal injury 72.76 14.98 50 12696 12005 32488775
Anhedonia 70.54 14.98 43 12703 8421 32492359
Injury 68.44 14.98 62 12684 22183 32478597
Hypotension 64.15 14.98 208 12538 215902 32284878
Acute generalised exanthematous pustulosis 64.00 14.98 37 12709 6576 32494204
Emotional distress 59.31 14.98 50 12696 16256 32484524
Fatigue 57.82 14.98 33 12713 350668 32150112
Drug reaction with eosinophilia and systemic symptoms 55.44 14.98 66 12680 32419 32468361
Hypovitaminosis 53.16 14.98 16 12730 533 32500247
Vitamin K deficiency 48.12 14.98 13 12733 291 32500489
Urticaria 46.98 14.98 84 12662 59530 32441250
Blood pressure decreased 44.18 14.98 75 12671 51005 32449775
Shock 42.80 14.98 50 12696 24064 32476716
Erythema 42.68 14.98 98 12648 83007 32417773
Unevaluable event 41.25 14.98 58 12688 33528 32467252
Post procedural complication 40.22 14.98 35 12711 11872 32488908
Death 40.15 14.98 55 12691 382462 32118318
Vitamin K decreased 39.35 14.98 8 12738 47 32500733
Bronchospasm 36.59 14.98 32 12714 10923 32489857
Dizziness 35.51 14.98 19 12727 209599 32291181
Rash 34.72 14.98 168 12578 209165 32291615
Post procedural haematoma 33.22 14.98 15 12731 1589 32499191
Stress 30.58 14.98 42 12704 23740 32477040
Hyperthermia malignant 30.36 14.98 15 12731 1944 32498836
Metabolic acidosis 30.33 14.98 56 12690 40643 32460137
Renal impairment 29.42 14.98 91 12655 91881 32408899
Adrenal suppression 29.23 14.98 11 12735 733 32500047
Multiple organ dysfunction syndrome 29.06 14.98 76 12670 69778 32431002
Hepatic function abnormal 28.88 14.98 58 12688 44782 32455998
Jaundice cholestatic 28.87 14.98 20 12726 4858 32495922
Pyrexia 28.83 14.98 219 12527 319749 32181031
Post procedural hypotension 28.49 14.98 6 12740 43 32500737
Gastritis fungal 28.30 14.98 7 12739 109 32500671
Brain herniation 28.05 14.98 18 12728 3853 32496927
Weight decreased 27.80 14.98 15 12731 164803 32335977
Coagulation factor X level decreased 27.55 14.98 5 12741 14 32500766
Ventricular tachycardia 26.83 14.98 41 12705 25515 32475265
Pseudomonal sepsis 26.81 14.98 16 12730 3013 32497767
Tubulointerstitial nephritis 25.81 14.98 35 12711 19542 32481238
Rash maculo-papular 25.35 14.98 42 12704 27980 32472800
Post procedural haemorrhage 25.25 14.98 23 12723 8277 32492503
Anaesthetic complication 25.11 14.98 11 12735 1084 32499696
Serotonin syndrome 24.94 14.98 34 12712 19083 32481697
Pericarditis fungal 24.84 14.98 7 12739 184 32500596
Conjunctival ulcer 23.48 14.98 5 12741 38 32500742
Linear IgA disease 23.31 14.98 12 12734 1696 32499084
Toxic epidermal necrolysis 22.99 14.98 34 12712 20559 32480221
Disseminated intravascular coagulation 22.68 14.98 36 12710 23140 32477640
Laryngeal oedema 22.42 14.98 15 12731 3444 32497336
Renal failure 22.29 14.98 108 12638 134370 32366410
Malaise 22.24 14.98 22 12724 177116 32323664
Meningitis fungal 22.14 14.98 6 12740 136 32500644
Intrapericardial thrombosis 21.42 14.98 5 12741 60 32500720
Type I hypersensitivity 21.32 14.98 10 12736 1155 32499625
Spontaneous haematoma 21.17 14.98 8 12738 539 32500241
Drug hypersensitivity 21.07 14.98 70 12676 73330 32427450
Post embolisation syndrome 20.91 14.98 5 12741 67 32500713
Tachycardia 20.59 14.98 73 12673 79015 32421765
Device related infection 20.58 14.98 30 12716 17903 32482877
Drug eruption 20.47 14.98 31 12715 19135 32481645
Drug-induced liver injury 20.35 14.98 35 12711 24028 32476752
Factor V inhibition 19.99 14.98 6 12740 198 32500582
Headache 19.72 14.98 29 12717 196168 32304612
Clostridium difficile colitis 19.47 14.98 26 12720 14305 32486475
Kidney transplant rejection 18.87 14.98 19 12727 7736 32493044
Dysbiosis 18.82 14.98 7 12739 451 32500329
Eyelid oedema 18.78 14.98 16 12730 5273 32495507
Viral uveitis 18.60 14.98 4 12742 32 32500748
Coagulopathy 18.59 14.98 30 12716 19547 32481233
Coagulation factor VII level decreased 18.14 14.98 5 12741 121 32500659
Cardiac valve vegetation 17.78 14.98 7 12739 527 32500253
Systemic mastocytosis 17.65 14.98 5 12741 134 32500646
Myoclonus 17.56 14.98 25 12721 14604 32486176
Asthenia 17.44 14.98 42 12704 235902 32264878
Toxicity to various agents 17.23 14.98 27 12719 178014 32322766
Shock haemorrhagic 17.12 14.98 21 12725 10624 32490156
Haemolytic anaemia 17.06 14.98 21 12725 10663 32490117
Appendicitis perforated 17.02 14.98 10 12736 1830 32498950
Pruritus 16.94 14.98 97 12649 128605 32372175
Arteritis 16.66 14.98 6 12740 353 32500427
Pneumonia staphylococcal 16.47 14.98 12 12734 3156 32497624
Drug chemical incompatibility 16.38 14.98 3 12743 9 32500771
Blood creatine phosphokinase MB increased 16.35 14.98 10 12736 1967 32498813
Product dose omission issue 16.33 14.98 10 12736 102565 32398215
Procedural hypotension 16.17 14.98 8 12738 1040 32499740
Nodal rhythm 16.06 14.98 9 12737 1506 32499274
Toxic shock syndrome 15.77 14.98 6 12740 412 32500368
Electrocardiogram ST segment elevation 15.73 14.98 14 12732 4886 32495894
Angioedema 15.60 14.98 40 12706 36249 32464531
Diarrhoea 15.55 14.98 82 12664 364720 32136060
Acinetobacter infection 15.53 14.98 8 12738 1132 32499648
Arthrofibrosis 15.48 14.98 4 12742 75 32500705
Prothrombin level decreased 15.02 14.98 8 12738 1212 32499568
Delayed recovery from anaesthesia 15.01 14.98 7 12739 798 32499982

Pharmacologic Action:

SourceCodeDescription
ATC J01DB04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Pneumonia due to Streptococcus indication 34020007
Lower respiratory tract infection indication 50417007
Bacterial pneumonia indication 53084003 DOID:874
Cholangitis indication 82403002 DOID:9446
Infection of bone indication 111253001
Bacterial endocarditis indication 301183007
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Genitourinary Tract Infections indication
Prevention of Perioperative Infection indication
Prevention of Bacterial Endocarditis off-label use
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.22 acidic
pKa2 12.21 acidic
pKa3 1.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4019659 VUID
N0000147751 NUI
D00905 KEGG_DRUG
27164-46-1 SECONDARY_CAS_RN
C0007546 UMLSCUI
CHEBI:474053 CHEBI
CHEMBL1435 ChEMBL_ID
CHEMBL1200523 ChEMBL_ID
D002437 MESH_DESCRIPTOR_UI
DB01327 DRUGBANK_ID
10935 IUPHAR_LIGAND_ID
2991 INN_ID
IHS69L0Y4T UNII
33255 PUBCHEM_CID
203171 RXNORM
35509 MMSL
4371 MMSL
948 MMSL
d00007 MMSL
002720 NDDF
004841 NDDF
387470007 SNOMEDCT_US
80972005 SNOMEDCT_US
81088002 SNOMEDCT_US
4017460 VANDF
4019659 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9261 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9262 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9665 INJECTION, POWDER, FOR SOLUTION 20 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9923 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9924 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9983 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 23 sections
Cefazolin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0264-3103 SOLUTION 1 g INTRAVENOUS NDA 27 sections
Cefazolin Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0264-3105 SOLUTION 2 g INTRAVENOUS NDA 27 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3503 INJECTION, SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0338-3508 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 26 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9833 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 14 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9834 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 10 sections
CEFAZOLIN HUMAN PRESCRIPTION DRUG LABEL 1 0404-9835 INJECTION, POWDER, FOR SOLUTION 225 mg INTRAMUSCULAR ANDA 11 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0409-2585 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3450 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3451 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3452 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-100 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-100 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-101 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-101 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-102 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 25021-102 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 24 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-120 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-706 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-707 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 44567-708 INJECTION, POWDER, FOR SOLUTION 10 g INTRAVENOUS ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 50090-2238 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 21 sections
Cefazolin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4256 INJECTION, POWDER, FOR SOLUTION 330 mg INTRAMUSCULAR ANDA 24 sections